These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16219569)
1. Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Langer C; Lengfelder E; Thiele J; Kvasnicka HM; Pahl HL; Beneke H; Schauer S; Gisslinger H; Griesshammer M Haematologica; 2005 Oct; 90(10):1333-8. PubMed ID: 16219569 [TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640 [TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon for the treatment of high-risk essential thrombocythemia. Mesa R Haematologica; 2005 Oct; 90(10):1298B. PubMed ID: 16219553 [No Abstract] [Full Text] [Related]
4. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Alvarado Y; Cortes J; Verstovsek S; Thomas D; Faderl S; Estrov Z; Kantarjian H; Giles FJ Cancer Chemother Pharmacol; 2003 Jan; 51(1):81-6. PubMed ID: 12497210 [TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109 [TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Beauverd Y; Radia D; Cargo C; Knapper S; Drummond M; Pillai A; Harrison C; Robinson S Haematologica; 2016 May; 101(5):e182-4. PubMed ID: 26819057 [No Abstract] [Full Text] [Related]
7. Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). Sacchi S; Vinci G; Gugliotta L; Rupoli S; Gargantini L; Martinelli V; Baravelli S; Lazzarino M; Finazzi G Haematologica; 2000 May; 85(5):492-5. PubMed ID: 10800165 [TBL] [Abstract][Full Text] [Related]
8. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Mazza GL; Mead-Harvey C; Mascarenhas J; Yacoub A; Kosiorek HE; Hoffman R; Dueck AC; Mesa RA; Lancet Haematol; 2022 Jan; 9(1):e38-e48. PubMed ID: 34971581 [TBL] [Abstract][Full Text] [Related]
9. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Homoncik M; Ferlitsch A; Ferenci P; Formann E; Jilma B; Gangl A; Panzer S; Peck-Radosavljevic M Aliment Pharmacol Ther; 2005 Jan; 21(1):49-55. PubMed ID: 15644045 [TBL] [Abstract][Full Text] [Related]
10. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G; Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737 [TBL] [Abstract][Full Text] [Related]